Completed PHASE2 INTERVENTIONAL 1-arm NCT00287287

REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas

Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas

Sponsor: Celgene Corporation

Conditions Thyroid Neoplasms

Interventions Lenalidomide

Updated 10 times since 2017 Last updated: May 28, 2020 Started: Feb 28, 2006 Primary completion: Jul 6, 2010 Completion: Jul 6, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Thyroid Neoplasms, this trial is completed. The trial is conducted by Celgene Corporation and has accumulated 10 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Jul 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Apr 2019 — Jul 2020 [monthly]

Active Not Recruiting PHASE2
Jun 2018 — Apr 2019 [monthly]

Active Not Recruiting PHASE2
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
Kenneth Ain

Data source: University of Kentucky

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lexington, United States